TransCode Therapeutics, Inc.
NASDAQ: RNAZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Philippe Calais
- Employees
- 7
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $4.7M
- Website
- https://www.transcodetherapeutics.com
Loading RNAZ…
Loading profile data…Frequently asked questions about RNAZ
What does TransCode Therapeutics, Inc. (RNAZ) do?
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanc...
Where does RNAZ trade?
TransCode Therapeutics, Inc. (RNAZ) trades on the NASDAQ Capital Market.
What sector is RNAZ in?
TransCode Therapeutics, Inc. (RNAZ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TransCode Therapeutics, Inc.?
Philippe Calais is the chief executive officer of TransCode Therapeutics, Inc. (RNAZ).
Where is TransCode Therapeutics, Inc. headquartered?
TransCode Therapeutics, Inc. is headquartered in United States.
Does RNAZ pay a dividend?
TransCode Therapeutics, Inc. (RNAZ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RNAZ go public?
TransCode Therapeutics, Inc. (RNAZ) completed its initial public offering in 2021.